Lurasidone Pharmacokinetics in Chinese Psychiatric Inpatients with Valproate Co-Medication

156 Chinese psychiatric inpatients provided 212 serum lurasidone concentrations for population pharmacokinetic modeling. The data was used to develop a one-compartment model identifying age and valproate co-medication as significant covariates affecting drug clearance. Author Ye Yang published the study on figshare under a CC-BY-4.0 license.

Use Cases

• Modeling the impact of valproate co-medication on lurasidone clearance based on the identified 47.7% increase.
• Simulating lurasidone concentration profiles stratified by patient age based on the established population pharmacokinetic model.
• Investigating the relationship between observed steady-state concentrations (3–11 ng/mL) and established therapeutic reference ranges.
• Assessing the need for adjusted therapeutic drug monitoring interpretation in Chinese psychiatric inpatients.

Strengths

• 212 serum concentration measurements from 156 patients provide a basis for population modeling.
• The analysis identified specific, quantifiable covariate effects, including a 47.7% increase in clearance with valproate co-medication.
• Model performance was assessed using multiple validation techniques, including bootstrap analysis and goodness-of-fit plots.

Limitations

• The dataset is small in file size (13.4 KB), suggesting limited raw data or a summary document.
• Column-level documentation is absent; field semantics must be inferred after download.
• Data may reflect geographic and clinical bias inherent to the single-center inpatient study.

Provenance

Source

figshare

Collection Method

Routine therapeutic drug monitoring data collected from psychiatric inpatients.

Freshness

Last updated 2026-05-12 05:26:55; freshness should be verified.

Geography

China